5/17
11:07 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
5/16
07:41 am
carm
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte [Yahoo! Finance]
Medium
Report
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte [Yahoo! Finance]
5/16
07:30 am
carm
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Medium
Report
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
5/14
07:08 am
carm
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation? [Yahoo! Finance]
Low
Report
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation? [Yahoo! Finance]
5/10
08:39 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
5/9
10:42 am
carm
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/9
07:40 am
carm
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
5/9
07:30 am
carm
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Neutral
Report
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
5/8
07:46 am
carm
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 [Yahoo! Finance]
Low
Report
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 [Yahoo! Finance]
5/8
07:30 am
carm
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
Low
Report
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
5/6
07:30 am
carm
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Medium
Report
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
5/2
07:44 am
carm
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer [Yahoo! Finance]
5/2
07:30 am
carm
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Medium
Report
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
4/24
05:18 pm
carm
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting [Yahoo! Finance]
4/24
05:05 pm
carm
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Low
Report
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
4/22
04:46 pm
carm
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting [Yahoo! Finance]
Medium
Report
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting [Yahoo! Finance]
4/22
04:35 pm
carm
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Medium
Report
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
4/11
08:00 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) is now covered by analysts at BTIG Research. They set a "buy" rating and a $6.00 price target on the stock.
Low
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) is now covered by analysts at BTIG Research. They set a "buy" rating and a $6.00 price target on the stock.
4/3
07:00 am
carm
Carisma Therapeutics to Present at Upcoming Conferences
Low
Report
Carisma Therapeutics to Present at Upcoming Conferences
4/2
09:01 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.
4/1
08:35 am
carm
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
High
Report
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4/1
07:00 am
carm
Carisma Therapeutics Announces Changes to its Board of Directors
High
Report
Carisma Therapeutics Announces Changes to its Board of Directors
3/21
05:00 pm
carm
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
2/28
07:30 am
carm
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
Low
Report
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference